INMUNOBIOLOGÍA del trasplante
TRASPLANTE
University Hospital of Geneva
Ginebra, SuizaPublicaciones en colaboración con investigadores/as de University Hospital of Geneva (9)
2019
2018
2017
-
Modulation of cytotoxic responses by targeting CD160 prolongs skin graft survival across major histocompatibility class I barrier
Translational Research, Vol. 181, pp. 83-95.e3
-
T follicular helper expansion and humoral-mediated rejection are independent of the HVEM/BTLA pathway
Cellular and Molecular Immunology, Vol. 14, Núm. 6, pp. 497-510
2013
-
ITIM-dependent negative signaling pathways for the control of cell-mediated xenogeneic immune responses
Xenotransplantation, Vol. 20, Núm. 6, pp. 397-406
2012
-
Selective blockade of herpesvirus entry mediator-B and T lymphocyte attenuator pathway ameliorates acute graft-versus-host reaction
Journal of Immunology, Vol. 188, Núm. 10, pp. 4885-4896
2010
-
HVEM/LIGHT/BTLA/CD160 cosignaling pathways as targets for immune regulation
Journal of Leukocyte Biology, Vol. 87, Núm. 2, pp. 223-235
2008
-
PD-1/PD-L1, PD-1/PD-L2, and other co-inhibitory signaling pathways in transplantation
Transplant International, Vol. 21, Núm. 11, pp. 1015-1028
2007
-
Blockade of the PD-1/PD-1L pathway reverses the protective effect of anti-CD40L therapy in a rat to mouse concordant islet xenotransplantation model
Xenotransplantation, Vol. 14, Núm. 3, pp. 243-248